Patents Represented by Attorney, Agent or Law Firm Rose Ann Dabek
-
Patent number: 6340696Abstract: A pharmaceutical composition that inhibits or slows the growth of viruses in animals, particularly in mammals, while reducing cytoxicity of ribavirin or interferon is disclosed. This same composition can be used to treat viral infections, particularly hepatitis C. The composition preferably comprises from about 10 mg to about 6000 mg of a (5-aryl-1,2,4-thiadiazol)-3-yl thiourea derivative or (5-aryl-1,2,4-thiadiazol)-3-yl urea derivative of the formula: wherein X is oxygen or sulfur, R is hydrogen or alkyl having from 1-3 carbons, n is 0-4, R1 is independently selected from the group consisting of hydrogen, alkyl having from 1 to 7 carbon atoms, chloro, bromo or fluoro, oxychloro, alkoxy having the formula —O(CH2)yCH3, wherein y is from 1 to 6, or a pharmaceutically acceptable acid addition salt or prodrug thereof and a safe and effective amount of ribavirin, interferon or mixtures thereof. The preferred compound is (5-phenyl-1,2,4-thiadazol-3-yl) thiourea.Type: GrantFiled: September 15, 2000Date of Patent: January 22, 2002Assignee: The Procter & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6329355Abstract: A method for inhibiting the growth of tumors and cancers in mammals comprising administering a chemotherapeutic agent to significantly reduce the tumor in mass and then administering a benzimidazole derivative. Potentiators can also be included in the benzimidazole composition.Type: GrantFiled: April 19, 2000Date of Patent: December 11, 2001Assignee: The Procter & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6297384Abstract: 3-[N′-(benzoyl)thioureido]-5-substituted-1,2,4-thiadiazoles are debenzoylated in an aqueous KOH solution. This process provides the 5-substituted-3-thioureido-1,2,4-thiadiazoles in unexpectedly high yield and purity as compared to similar processes employing NaOH.Type: GrantFiled: December 21, 1999Date of Patent: October 2, 2001Assignee: The Procter & Gamble CompanyInventor: Joseph K. Agyin
-
Patent number: 6290929Abstract: This invention is a method of treating cancer, including carcinomas and sarcomas, through the administration of a pharmaceutical composition containing an arylaldehyde 5-oxo-1,2,4-triazine hydrazide derivative. The arylaldehyde 5-oxo-1,2,4-triazine hydrazide derivative is selected from the group consisting of those with the formula: wherein R and R1 are independently selected from the group consisting of hydrogen and alkyl wherein the alkyl group has up to 7 carbon atoms; or a pharmaceutical salt thereof; a prodrug thereof; a metabolite thereof; and mixtures thereof. Pharmaceutical compositions comprising these compounds and their use in various treatment methods are claimed. The compounds can be used in conjunction with other chemotherapeutic agents and potentiators.Type: GrantFiled: July 28, 2000Date of Patent: September 18, 2001Assignee: The Procter & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6271217Abstract: A method for inhibiting the growth of tumors and cancers in mammals comprising administering a chemotherapeutic agent to significantly reduce the tumor in mass and then administering a benzimidazole derivative. Potentiators can also be included in the benzimidazole composition.Type: GrantFiled: December 22, 1998Date of Patent: August 7, 2001Assignee: The Procter & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6265427Abstract: Method of treating leukemia, inhibiting the growth or proliferation of leukemic cells or extending the life span of a animal having leukemia are disclosed. The methods comprise the step of treating the leukemia with an effective amount of a compound of the Formula I or a pharmaceutically acceptable salt or prodrug form thereof, wherein: X is hydrogen, halogen or alkyl of less than 7 carbon atoms; n is a positive integer of less than 4; Y is hydrogen, chlorine, nitro, methyl or ethyl; R is hydrogen or an alkyl group of from 1 to 8 carbon atoms, alkylcarbamyl; R2 is 4-thiazolyl or NHCOOR1; and R1 is an aliphatic hydrocarbon of less than 7 carbon atoms. A chemotherapeutic agent and/or potentiator can be used in conjunction with the compound of the Formula I.Type: GrantFiled: August 16, 1999Date of Patent: July 24, 2001Assignee: The Proctor & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6262093Abstract: This invention is a method of treating cancer, both carcinomas and sarcomas, and viral infections, in particular HIV through the administration of a pharmaceutical composition containing a benzimidazole derivative. The composition is also claimed.Type: GrantFiled: March 9, 1999Date of Patent: July 17, 2001Assignee: The Proctor & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6258831Abstract: Methods are disclosed to treat viral infections, particularly hepatitis C, herpes simplex, Kaposi's sarcoma and HIV, comprising administrating a (5-aryl-1,2,4-thiadiazol)-3-yl thiourea derivative or (5-aryl-1,2,4-thiadiazol)-3-yl urea derivative of the formula: wherein X is oxygen or sulfur, R is hydrogen or alkyl having from 1-3 carbons, n is 0-4, R1 is independently selected from the group consisting of hydrogen, alkyl having from 1 to 7 carbon atoms, chloro, bromo or fluoro, oxychloro, alkoxy having the formula —O(CH2)yCH3 wherein y is from 1 to 6, or a pharmaceutically acceptable acid addition salt or prodrug thereof. The preferred compound is (5-phenyl-1,2,4-thiadazol-3-yl) thiourea.Type: GrantFiled: March 27, 2000Date of Patent: July 10, 2001Assignee: The Procter & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6251870Abstract: This invention is a pharmaceutical composition that inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition contains N-chlorophenylcarbamates and N-chlorophenylthiocarbamates along with a chemotherapeutic agent and optionally a potentiator. A composition for treating viral infections in animals or humans comprising a safe and effective amount of N-chlorophenylcarbamates and the N-chlorophenylthiocarbamates and a potentiator is also disclosed.Type: GrantFiled: July 30, 1999Date of Patent: June 26, 2001Assignee: The Procter & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6245789Abstract: A pharmaceutical composition that can be used to treat viral infections, particularly HIV. The composition comprises from about 250 mg to about 6000 mg of a benzimidazole derivative of the formula: wherein X is hydrogen, halogen, alkyl of less than 7 carbon atoms or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 4; Y is hydrogen, chlorine, nitro, oxychloro, methyl or ethyl; and R is hydrogen or an alkyl group having from 1 to 8 carbon atoms, and R2 is 4-thiazolyl and the pharmaceutically acceptable organic or inorganic addition salts thereof. The preferred compound is thiabendazole. In the present invention it has been discovered that the compounds described above are useful for the inhibition of HIV and the treatment of HIV infection when used alone or in combination with other anti-viral agents.Type: GrantFiled: May 17, 1999Date of Patent: June 12, 2001Assignee: The Procter & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6245788Abstract: A pharmaceutical composition that inhibits or slows the infection or reinfection of animals, particularly mammals, by HIV or other retroviruses is disclosed. The composition comprises from about 10 mg to about 6000 mg of a (5-aryl-1,2,4-thiadiazol)-3-yl thiourea derivative or (5-aryl-1,2,4-thiadiazol)-3-yl urea derivative of the formula: wherein X is oxygen or sulfur, R is hydrogen or alkyl having from 1-3 carbons, n is 1-4, R1is independently selected from the group consisting of hydrogen, alkyl having from 1 to 7 carbon atoms, chloro, bromo or fluoro, oxychloro, alkoxy having the formula —O(CH2)yCH3 wherein y is from 1 to 6, or a pharmaceutically acceptable acid addition salt or prodrug thereof.Type: GrantFiled: March 27, 2000Date of Patent: June 12, 2001Assignee: The Procter & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6228876Abstract: A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals that comprises a material is disclosed. The particular material used is a 1H-1,2,4-triazole derivative. These compounds can also be used to treat viral infections.Type: GrantFiled: December 22, 1999Date of Patent: May 8, 2001Assignee: The Procter & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6225307Abstract: A pharmaceutical composition that inhibits or slows the growth of viruses in animals, particularly in mammals, is disclosed. This same composition is can be used to treat viral infections, particularly HIV. The composition comprises from about 10 mg to about 10000 mg of a carbamic acid ester derivative of the formula: wherein X is independently oxygen or sulfur, R is selected from the group consisting of hydrogen and alkyl having from 1 to 4 carbon atoms, R1 is selected from the group consisting of hydrogen and alkyl having from 1 to 4 carbon atoms, wherein R2 is independently selected from the group consisting of hydrogen and alkyl having from 1 to 4 carbon atoms, and wherein Y is selected from the group consisting of hydrogen, chloro, fluoro, bromo, hydroxy, oxychloro and sulfhydryl or pharmaceutical addition salt or prodrug thereof. The most preferred compound is (4-chlorophenyl)-carbamic acid, 3-(hexahydro-3-ethyl-1-methyl-2-oxo-1H-azepin-3-yl) 2 phenyl ester.Type: GrantFiled: March 29, 2000Date of Patent: May 1, 2001Assignee: The Procter & Gamble CompanyInventors: James Berger Camden, Joseph Herman Gardner, David Thomas Stanton
-
Patent number: 6200992Abstract: A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals that comprises a 1H-1,2,4-triazole derivative along with a safe and effective amount of a chemotherapeutic agent. Potentiators can be used to enhance the effectiveness of the drugs. The triazoles and potentiators compounds can also be used to treat viral infections.Type: GrantFiled: July 16, 1996Date of Patent: March 13, 2001Assignee: The Procter & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6194430Abstract: A pharmaceutical composition is disclosed to treat viral infections, particularly HIV and hepatitis, as well as to treat fungal infections of the genus cryptococcus neoformans or curvularai lunata. The composition comprises from about 10 mg to about 6000 mg of a 2-thienyl-imidazolo [4,5]pyridine of the formula: wherein n is from 1 to 4, R is selected from the group consisting of hydrogen, alkyl having from 1 to 7 carbon atoms, chloro, bromo or fluoro, oxychloro, hydroxy, sulfhydryl, alkoxy having the formula —O(CH2)yCH3 wherein y is from 1 to 6, the prodrugs thereof, and the pharmaceutically acceptable salts thereof. The preferred anti-viral compound is or its hydrochloride salt.Type: GrantFiled: March 29, 2000Date of Patent: February 27, 2001Assignee: The Procter & Gamble CompanyInventors: James Berger Camden, Joseph Herman Gardner, David Thomas Stanton
-
Patent number: 6177460Abstract: Methods for the treatment of cancers or viral infections in mammals are disclosed that include administration of an N-chlorophenylcarbamate, or an N-chlorophenylthiocarbamate, or a salt thereof. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.Type: GrantFiled: September 29, 1999Date of Patent: January 23, 2001Assignee: The Procter & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6110953Abstract: A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals that comprises a 1H-1,2,4-triazole derivative along with a safe and effective amount of a chemotherapeutic agent. Potentiators can be used to enhance the effectiveness of the drugs. The triazoles and potentiators compounds can also be used to treat viral infections.Type: GrantFiled: February 5, 1999Date of Patent: August 29, 2000Assignee: The Procter & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6090796Abstract: This invention is a pharmaceutical composition that inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition contains N-phosphonoglycine derivatives which are systemic herbicides in combination with chemotherapeutic agents for treatment of cancers and tumors. N-phosphonoglycine derivatives can be used to treat viral infections, particularly herpes infections. Optionally potentiators can be included.Type: GrantFiled: December 24, 1998Date of Patent: July 18, 2000Assignee: The Procter & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6080431Abstract: Nutritional mineral supplements comprising calcium citrate malate and vitamin D are disclosed. Estrogen can also be used with these supplements. These supplements, which provide at least 25% RDA of calcium and vitamin D are used in addition to the normal diet. These supplements are useful for increasing bone growth and for treating age-related bone loss in humans and animals.Type: GrantFiled: January 6, 1995Date of Patent: June 27, 2000Assignee: The Procter & Gamble CompanyInventors: Mark Benson Andon, Kenneth Thomas Smith
-
Patent number: RE37003Abstract: A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals comprising fungicide is disclosed. The particular fungicide used is a 1,3-bis-triazolyl-2-propanol derivative. These compositions are also effective against viral infections.Type: GrantFiled: August 5, 1999Date of Patent: December 26, 2000Assignee: The Procter & Gamble CompanyInventor: James Berger Camden